摘要
目的 探讨卡瑞利珠单抗联合小剂量阿帕替尼二线治疗复发转移性食管癌患者的临床疗效。方法根据治疗方法的不同将137例行二线治疗的食管癌患者分为对照组(n=56)和观察组(n=81),对照组患者采取卡瑞利珠单抗治疗,观察组患者在对照组的基础上采取小剂量阿帕替尼治疗。比较两组患者的临床疗效、不良反应发生情况及生存情况。结果 观察组患者的临床疗效明显优于对照组,差异有统计学意义(P﹤0.01)。观察组患者的客观缓解率(ORR)和疾病控制率(DCR)分别为41.98%(34/81)、70.37%(57/81),分别明显高于对照组患者的16.07%(9/56)、44.64%(25/56),差异均有统计学意义(P﹤0.01)。两组患者各不良反应发生情况比较,差异均无统计学意义(P﹥0.05)。至随访结束,观察组患者中位总生存期为12个月(95%CI:10.346~13.654),明显长于对照组患者的9个月(95%CI:8.341~9.659),差异有统计学意义(P﹤0.01)。结论 卡瑞利珠单抗联合小剂量阿帕替尼二线治疗复发转移性食管癌患者能够提高临床疗效,延长生存时间,且具有一定的安全性。
Objective To explore the clinical efficacy of camrelizumab combined with low-dose apatinib as secondline treatment for patients with recurrent and metastatic esophageal cancer.Method According to different treatment methods,137 patients with esophageal cancer who underwent second-line treatment were divided into the control group(n=56)and the observation group(n=81).Patients in the control group were treated with camrelizumab,while patients in the observation group were treated with low-dose apatinib on the basis of the control group.The clinical efficacy,adverse reactions and survival of the two groups were compared.Result The clinical efficacy of the observation group was significantly better than that of the control group,and the difference was statistically significant(P<0.01).The objective response rate(ORR)and disease control rate(DCR)of the observation group were 41.98%(34/81)and 70.37%(57/81),respectively,which were significantly higher than 16.07%(9/56)and 44.64%(25/56)of the control group,the differences were statistically significant(P<0.01).There were no statistically significant differences in the incidences of adverse reaction between the two groups(P>0.05).By the end of the follow-up,the median overall survival of the observation group was 12 months(95%CI:10.346-13.654),which was significantly longer than 9 months(95%CI:8.341-9.659)of the control group,and the difference was statistically significant(P<0.01).Conclusion Camrelizumab combined with low-dose apatinib as second-line treatment for patients with recurrent and metastatic esophageal cancer can improve clinical efficacy,prolong survival time,and has certain safety.
作者
刘勤
雷彩鹏
范俊利
陈强
张卫国
吴晓鹏
赵安顺
LIU Qin;LEI Caipeng;FAN Junli;CHEN Qiang;ZHANG Weiguo;WU Xiaopeng;ZHAO Anshun(Department of Thoracic Oncology Surgery,the First Affiliated Hospital of He’nan University of Science and Technology,Luoyang 471000,He’nan,China)
出处
《癌症进展》
2025年第20期2400-2403,共4页
Oncology Progress
关键词
复发转移性食管癌
二线治疗
卡瑞利珠单抗
阿帕替尼
recurrent and metastatic esophageal cancer
second-line treatment
camrelizumab
apatinib
